Compare Gilead Sciences, Inc. (GILD) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KeyCorp — how do they compare? Gilead Sciences, Inc. trades at $133.34 (market cap $163.51B), while KeyCorp trades at $23.94 (market cap $25.40B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× KeyCorp's market cap, and KeyCorp pays the higher dividend (3.48%). Which is the better fit depends on your goals.
| GILD | KEY | |
|---|---|---|
Market Cap | $163.51B | $25.40B |
Sector | Health | Financials |
52-Week High | $155.80 | $23.53 |
52-Week Low | $108.22 | $16.78 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
KeyCorp (KEY) trades at $23.96, up 2.83% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.44 exceeding the $0.4135 estimate. Fundamentals are solid, with a P/E of 14.44 and net income margin of 26.05% for 2025. Recent news highlights dividend declarations and strategic partnerships, reinforcing positive momentum.
The outlook for KEY is favorable, driven by earnings growth and a $3 billion buyback program. Risks include interest rate sensitivity and competitive pressures. With a consensus price target of $29.32, upside potential exists, but investors should monitor economic conditions affecting regional banks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
